Stocks of these 21 cos tumble over 20% in 1 year as profits slump for… The financial year gone up was a mixed bag for India Inc as many companies managed to… Read More...
Pharma Inc gets back to life beyond Covid In FY23, the company is targeting 130 drug launches in the emerging markets, of which… Read More...
Can Divi’s maintain its premium valuation amid headwinds? SynopsisIndian pharma companies have been struggling to maintain margins because of… Read More...
Pricing pressures, high raw material costs could cast damper on Q4… NEW DELHI: Amid what has so far been a mixed scorecard for India Inc’s fourth quarter… Read More...
Pharma companies may see stock valuations plateau in near term Product-specific demand during the quarter nevertheless aided the performance of some… Read More...
